| アブストラクト | OBJECTIVES: The aim of this research was to describe the cases of TNF-alpha antagonist-related alopecia reported in the French Pharmacovigilance Database (FPVD) and to investigate the association between exposure to TNF-alpha antagonists and occurrence of alopecia. METHODS: All spontaneous reports of TNF-alpha antagonist-related alopecia recorded in the FPVD between January 2000 and April 2012 were colligated and described. We conducted disproportionality analyses (case/non-case method) to assess the link between the occurrence of alopecia and exposure to TNF-alpha antagonists. Cases were all reports of alopecia and non-cases were all other reports recorded during the study period. Exposure to TNF-alpha antagonists was sought in cases and in non-cases. Reporting odds ratios (RORs) were calculated to assess the association. Docetaxel was used as positive control and acetaminophen as negative control. We performed sensitivity analyses excluding cases of androgenic alopecia and those occurring in psoriatic patients. RESULTS: Among 282 590 spontaneous reports of adverse drug reactions (ADRs) collated in the FPVD, 1068 cases (alopecia reports) were identified. Of these cases, 52 (4.9%) occurred during exposure to TNF-alpha antagonists (18 involved infliximab, 17 adalimumab, 15 etanercept and 2 certolizumab). Exposure to TNF-alpha antagonists was more frequent among alopecia reports than among other ADR reports for all TNF-alpha antagonists pooled (ROR 3.0, 95% CI 2.3, 4.0) as well as for each antagonist separately, with similar values. Sensitivity analyses yielded similar results. The RORs were 29.9 (95% CI 25.3, 35.5) with docetaxel and 0.3 (95% CI 0.2, 0.4) with acetaminophen. CONCLUSION: The present study confirms a strong link between TNF-alpha antagonist exposure (class effect) and the occurrence of alopecia. |
|---|
| 組織名 | Regional Centre of Pharmacovigilance, Lille University Hospital, University of;Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital,;University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and;Clinical Immunology Department, Lille University Hospital, Immunology Laboratory;EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune;Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes;and Rheumatology Department, Nancy University Hospital, Nancy, France.Regional;Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2,;Lille, Internal Medicine Department, Toulouse University Hospital, University of;Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical;Immunology Department, Lille University Hospital, Immunology Laboratory EA2686,;Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital,;Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and;Rheumatology Department, Nancy University Hospital, Nancy, France.;johana.bene@chru-lille.fr.;Rheumatology Department, Nancy University Hospital, Nancy, France.Regional Centre;of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille,;Internal Medicine Department, Toulouse University Hospital, University of;and Rheumatology Department, Nancy University Hospital, Nancy, France. |
|---|
